Low cost spearheads China drive into biotech – Ben Hirschler

From Reuters:

China aims to become a leading player in the fast-growing sector by capitalising on research costs that are one fifth those of Europe or the , a top official said on Monday.

In the past, the country’s drug has largely consisted of manufacturing cheap generics and producing traditional Chinese medicine.

Now the government is making biotechnology a priority, Professor Wang Hongguang, director general of the China National Center for Biotechnology Development, told a pharmaceutical in London.

Open popup

Welcome back!

CDT is a non-profit media site, and we need your support. Your contribution will help us provide more translations, breaking news, and other content you love.